Neonatal Sepsis: Within and Beyond China

Neonatal sepsis—an infection in newborns that can rapidly turn life-threatening—remains a major global health challenge. Globally, it affects an estimated 2,202 per 100,000 live births, with mortality rates between 11% and 19%. But how does this play out in China, a country with vast regional differences in healthcare access and a population of over 1.4 billion? Recent research reveals unique patterns in neonatal sepsis incidence, pathogens, and treatment challenges in China—differences that could hold key lessons for improving care worldwide.

In this article, we break down the latest findings on neonatal sepsis in China and beyond, drawing on a 2020 review by Ying Dong (Children’s Hospital of Fudan University, Shanghai) and colleagues published in the Chinese Medical Journal. We’ll explore why China’s approach to preventing early-onset sepsis differs from the U.S. and Europe, the underrecognized role of viruses in late-onset sepsis, and the urgent need to address antibiotic resistance in newborn care.

What Is Neonatal Sepsis?

Neonatal sepsis is a systemic infection in babies younger than 28 days (or 44 weeks post-conception for preterm infants). It’s divided into two types based on when symptoms start:

Early-onset sepsis (EOS): Develops within the first 3–6 days of life, usually from bacteria passed from mother to baby during pregnancy or delivery (e.g., Group B Streptococcus, E. coli).
Late-onset sepsis (LOS): Occurs after 4–7 days, often from hospital environments (e.g., central line infections) or community exposure (e.g., viral spread from caregivers).

Premature babies and those with very low birth weight (<1,500 grams) are at highest risk—their immune systems are not fully developed, and they often need invasive medical devices (like breathing tubes or IV lines) that can introduce bacteria.

Early-Onset Sepsis (EOS): China vs. the West

In the U.S. and Europe, EOS is most often caused by Group B Streptococcus (GBS)—a bacteria that colonizes 10–30% of pregnant women’s genital or intestinal tracts. Without treatment, 1–2% of babies exposed to GBS during delivery will develop EOS, which can cause meningitis, pneumonia, or death.

To prevent this, the American College of Obstetricians and Gynecologists (ACOG) recommends universal GBS screening for all pregnant women between 36–38 weeks. Women with positive results get intrapartum antibiotic prophylaxis (IAP)—usually penicillin—during labor to reduce transmission. This strategy has cut GBS EOS rates in the U.S. by 80% since the 1990s.

But China’s EOS picture is different. A 2015–2018 study of 25 tertiary neonatal units in China found:

EOS incidence was 9.7 per 1,000 live births (higher than the U.S. rate of ~0.8 per 1,000).
Gram-negative bacteria (GNB) like E. coli (20.3%) were the top cause, followed by coagulase-negative staphylococci (16.5%).
GBS caused just 2.5% of EOS cases—far less than in the U.S. or Europe.

Why the difference? China has no national GBS screening guidelines. Some hospitals use a risk-based approach (e.g., giving IAP to women with preterm labor or fever), while others follow ACOG’s universal screening. Maternal GBS colonization rates in China are also lower—5.7–14.5%, compared to 10–30% in the U.S.

But there’s a catch: Even with low GBS rates, EOS in China has a 19% death rate (61 of 321 cases). The leading cause? GNB like E. coli, which are often resistant to common antibiotics.

Late-Onset Sepsis (LOS): The Hidden Risks

LOS accounts for ~60% of sepsis cases in NICUs worldwide. Unlike EOS, it’s often linked to:

Maternal post-partum transmission: A 2013 Italian study found 22% of newborns were colonized with GBS from their mothers after delivery—even if the mother had IAP. Six mothers had GBS in their breast milk, and genetic testing confirmed the same strain in mother and baby.
Gram-negative bacteria (GNB): While less common than Gram-positive bacteria (e.g., staph), GNB like E. coli cause more severe illness (e.g., meningitis) and higher mortality—especially in premature babies. A French study of 325 infants with E. coli meningitis found 9.2% died, with very preterm birth (before 32 weeks) being a key risk factor.
Hospital vs. community-acquired infection: A Swiss study found hospital-acquired LOS (onset >48 hours after NICU admission) was most often caused by coagulase-negative staphylococci or S. aureus. Community-acquired LOS (onset ≤48 hours after admission) was more likely from GBS or E. coli.

In China, LOS pathogens mirror global trends: Coagulase-negative staphylococci, S. aureus, and GNB like E. coli or Klebsiella are top causes. But hospital-acquired LOS is more common in preterm infants who need ventilators or central lines—devices that can act as “doorways” for bacteria.

Viral Sepsis: The Underrecognized Threat

When we think of neonatal sepsis, bacteria come to mind first. But viruses are a major, underdiagnosed cause—especially in LOS.

A 2018 study of 63,114 babies in Bangladesh, India, and Pakistan found 12% of suspected serious bacterial infections (pSBI) were actually viral. The top viral culprit? Respiratory syncytial virus (RSV), which affected 5.4 per 1,000 live births.

Two other viruses deserve attention:

Herpes simplex virus (HSV): Rare but deadly—0.4% of infants tested for HSV in U.S. emergency departments had the virus, with 80% of cases in the first 4 weeks of life. 68% of infected babies had central nervous system (CNS) or disseminated disease (affecting multiple organs). Early treatment with acyclovir is life-saving, but many infants don’t get tested.
Enteroviruses: These cause meningitis, fever without a source, and sepsis-like symptoms in newborns. A 2016 study of 334 febrile neonates in East China found 39.2% had enterovirus—most often detected in stool (99.2%) or spinal fluid (44.3%). A French study found blood PCR tests for enterovirus were more sensitive than spinal fluid tests, highlighting the need for broader viral screening.

Why does this matter? Viral sepsis doesn’t respond to antibiotics. Overusing antibiotics for viral infections drives resistance—a growing crisis in China.

Diagnosing Neonatal Sepsis: What Doctors Look For

Neonatal sepsis is tricky to diagnose: Symptoms (lethargy, poor feeding, low temperature) are vague, and newborns often don’t have fever. A prompt, thorough workup is key:

Blood culture: The “gold standard” for bacterial sepsis. Doctors need 1–2 mL of blood to optimize detection—too little can miss infections.
Urine culture: Done via sterile catheterization (not a bag sample) to rule out urinary tract infections (UTIs).
Spinal fluid (CSF) culture: A lumbar puncture (LP) to check for meningitis. For stable babies, LP should be done without prior brain imaging—delaying LP can worsen outcomes.
Biomarkers: Tests like procalcitonin (PCT) or C-reactive protein (CRP) help rule out bacterial infection, but they’re not perfect—viral infections or inflammation can also raise levels.

Two prediction rules help doctors identify low-risk infants:

Step-by-Step (Europe): Uses clinical appearance, age (0.5 ng/mL, CRP >20 mg/L) to categorize risk.
PECARN (U.S.): Uses urinalysis, absolute neutrophil count (ANC), and PCT to find febrile infants 60 days or younger at low risk of serious bacterial infection.

Treating Neonatal Sepsis: Balancing Speed and Stewardship

The first rule of sepsis treatment: Start antibiotics early. Delaying treatment increases death or disability risk.

Early-Onset Sepsis (EOS)

Empirical therapy: Ampicillin (covers GBS, strep) + gentamicin (covers GNB like E. coli).
If GBS is confirmed: Switch to ampicillin alone—stop gentamicin after 48 hours to avoid kidney or ear damage.
If ampicillin-resistant E. coli is found: Use a third-generation cephalosporin (e.g., cefotaxime) at higher doses (200 mg/kg/day) for meningitis.

Late-Onset Sepsis (LOS)

Hospital-acquired LOS: Vancomycin (covers methicillin-resistant staph) is first-line. If the central line is infected, remove it or use continuous vancomycin infusion.
GNB infections: Aminoglycosides (e.g., amikacin) are preferred—they have a narrow spectrum and lower resistance risk. If the baby has meningitis or ESBL-producing bacteria (resistant to cephalosporins), use carbapenems (e.g., meropenem).

The Antibiotic Resistance Crisis in China

Overuse of broad-spectrum antibiotics (e.g., third-gen cephalosporins, carbapenems) and poor stewardship have led to skyrocketing resistance in China:

50% of E. coli and Klebsiella are resistant to third-gen cephalosporins.
80% of E. coli are resistant to ampicillin (similar to the U.S. rate of 85%).
9% of E. coli and 6% of Klebsiella are resistant to carbapenems—last-resort antibiotics.

Why does this happen? Many doctors continue antibiotics even if cultures are negative, or use broad-spectrum drugs “just in case.” To fight back, hospitals need:

Antibiotic stewardship programs: Monitor use and guide appropriate prescribing.
Rapid diagnostic tests: PCR for viruses or bacteria to avoid unnecessary antibiotics.
Local surveillance: Track pathogen resistance patterns to tailor empiric therapy.

Key Takeaways for Parents and Providers

Neonatal sepsis is a global challenge, but China’s experience offers unique insights:

GBS screening isn’t one-size-fits-all: China’s low GBS colonization rates mean universal screening may not be cost-effective—risk-based strategies could work better.
Viruses matter: Test for enteroviruses, HSV, and RSV in febrile or septic newborns to avoid antibiotic overuse.
Resistance is urgent: China’s high rates of antibiotic-resistant GNB demand better stewardship—stop antibiotics if cultures are negative, and use narrow-spectrum drugs when possible.

For parents: If you’re pregnant, ask your doctor about GBS screening. Watch for sepsis symptoms in your newborn (lethargy, poor feeding, blue lips, fever or low temp) and seek care immediately.

For providers: Monitor local pathogen trends, use prediction rules to avoid overtesting, and collaborate with microbiologists to optimize treatment.

Neonatal sepsis is preventable and treatable—but only if we adapt care to local needs. China’s journey offers a roadmap for balancing global best practices with on-the-ground reality.

For more details, read the original 2020 review in the Chinese Medical Journal: doi.org/10.1097/CM9.0000000000000935

Was this helpful?

0 / 0